GSK
GSK plcNYSEHealthcare$56.69+1.25%OpenMarket Cap: $113.68B
As of 2026-04-06
Valuation
P/E (TTM)
19.89
PEG
0.16
P/B
5.26
P/S
2.63
EV/EBITDA
8.42
DCF Value
$176.49
FCF Yield
5.9%
Div Yield
2.9%
Margins & Returns
Gross Margin
72.5%
Operating Margin
21.9%
Net Margin
17.5%
ROE
37.2%
ROA
15.3%
ROIC
14.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $8.62B | 69.7% | $1.10B | $636.0M | $0.32 | $0.43 |
| FY 2025 | $31.95B | 72.5% | $7.01B | $5.59B | $2.72 | $1.69 |
| Q3 2025 | $8.55B | 73.6% | $2.59B | $2.01B | $0.98 | $0.43 |
| Q2 2025 | $7.99B | 72.9% | $2.02B | $1.44B | $0.70 | $0.43 |
| Q1 2025 | $7.52B | 74.2% | $2.22B | $1.62B | $0.78 | $0.41 |
| Q4 2024 | $8.12B | 68.5% | $696.0M | $414.0M | $0.20 | $0.38 |
| FY 2024 | $31.38B | 71.2% | $4.02B | $2.58B | $1.24 | $1.56 |
| Q3 2024 | $8.01B | 70.1% | $189.0M | $-58.0M | $-0.03 | $0.39 |
| Q2 2024 | $7.88B | 73.1% | $1.65B | $1.17B | $0.56 | $0.38 |
| Q1 2024 | $7.36B | 73.2% | $1.49B | $1.05B | $0.50 | $0.40 |
| Q4 2023 | $8.05B | 70.0% | $573.0M | $350.0M | $0.17 | $0.36 |
| FY 2023 | $30.33B | 71.8% | $6.75B | $4.93B | $2.40 | $1.39 |